RxDoctor Payments Data

Leanne Molia, MD

Ophthalmology · Port Jefferson Station, NYNPI 1003908831

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 126 payments — averaging $26.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$712
  • AbbVie$546
  • Alcon$377
  • Novartis$282
  • Shire North American Group Inc$187
  • plus $270 from 4 others

What the payments were for

  • Food & beverage$3,36199%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$91,804
Medicare patients
125
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost17$16,120
LumiganBimatoprost21$14,068
Travoprost46$13,117
RestasisCyclosporine13$11,192
VyzultaLatanoprostene Bunod11$5,810
TafluprostTafluprost/Pf17$3,451
Brinzolamide12$2,134
Latanoprost70$991
ErythromycinErythromycin Base37$397
Timolol Maleate11$313
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$225
Ofloxacin20$216
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$177
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim11$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$546$25,26034 claims
Aerie Pharmaceuticals, Inc.Rocklatan$1,003$16,12017 claims
Bausch & Lomb Americas Inc.Vyzulta$18$5,81011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →